CL2011003065A1 - Formulacion vesicular que comprende uno o mas fosfolipidos y uno o mas surfactantes no ionicos, libre de cualquier agente farmaceuticamente activo, util para el tratamiento del dolor asociado con osteoartritis. - Google Patents

Formulacion vesicular que comprende uno o mas fosfolipidos y uno o mas surfactantes no ionicos, libre de cualquier agente farmaceuticamente activo, util para el tratamiento del dolor asociado con osteoartritis.

Info

Publication number
CL2011003065A1
CL2011003065A1 CL2011003065A CL2011003065A CL2011003065A1 CL 2011003065 A1 CL2011003065 A1 CL 2011003065A1 CL 2011003065 A CL2011003065 A CL 2011003065A CL 2011003065 A CL2011003065 A CL 2011003065A CL 2011003065 A1 CL2011003065 A1 CL 2011003065A1
Authority
CL
Chile
Prior art keywords
osteoarthritis
phospholipids
useful
free
treatment
Prior art date
Application number
CL2011003065A
Other languages
English (en)
Inventor
George Langton Iliffe
John Charles Mayo
Matthias Rother
Ullrich Vierl
Original Assignee
John Charles Mayo
Ulrich Vierl
Matthias Rother
George Langton Iliffe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42785828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011003065(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by John Charles Mayo, Ulrich Vierl, Matthias Rother, George Langton Iliffe filed Critical John Charles Mayo
Publication of CL2011003065A1 publication Critical patent/CL2011003065A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

Formulación vesicular que comprende uno o más fosfolípidos y uno o más surfactantes, libre de cualquier agente farmacéuticamente activo, útil para el tratamiento del dolor de la inflamación o de la osteoartritis.
CL2011003065A 2009-06-03 2011-12-02 Formulacion vesicular que comprende uno o mas fosfolipidos y uno o mas surfactantes no ionicos, libre de cualquier agente farmaceuticamente activo, util para el tratamiento del dolor asociado con osteoartritis. CL2011003065A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18395609P 2009-06-03 2009-06-03
US31447810P 2010-03-16 2010-03-16
US32014810P 2010-04-01 2010-04-01

Publications (1)

Publication Number Publication Date
CL2011003065A1 true CL2011003065A1 (es) 2012-08-31

Family

ID=42785828

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011003065A CL2011003065A1 (es) 2009-06-03 2011-12-02 Formulacion vesicular que comprende uno o mas fosfolipidos y uno o mas surfactantes no ionicos, libre de cualquier agente farmaceuticamente activo, util para el tratamiento del dolor asociado con osteoartritis.

Country Status (25)

Country Link
US (2) US20120220669A1 (es)
EP (1) EP2437726B1 (es)
JP (2) JP2012528846A (es)
KR (1) KR20140021950A (es)
CN (4) CN105434354A (es)
AU (1) AU2010255391C1 (es)
BR (1) BRPI1010861A8 (es)
CA (1) CA2764227C (es)
CL (1) CL2011003065A1 (es)
CO (1) CO6480985A2 (es)
DE (1) DE112010001765T5 (es)
DK (1) DK2437726T3 (es)
EA (1) EA029132B1 (es)
ES (1) ES2682075T3 (es)
GB (1) GB2483419B (es)
IL (1) IL216737A (es)
LT (1) LT2437726T (es)
MX (1) MX349417B (es)
MY (1) MY170121A (es)
NZ (1) NZ597419A (es)
PL (1) PL2437726T3 (es)
PT (1) PT2437726T (es)
SG (1) SG176297A1 (es)
WO (1) WO2010140061A2 (es)
ZA (1) ZA201200017B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102770162B (zh) * 2009-08-21 2016-09-28 靶向递送技术有限公司 囊泡制剂
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
GB201206486D0 (en) * 2012-04-12 2012-05-30 Sequessome Technology Holdings Ltd Vesicular formulations and uses thereof
GB201208384D0 (en) 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, uses and methods
GB201208409D0 (en) * 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, kits and uses
CN105473162A (zh) * 2013-07-31 2016-04-06 斯昆申技术控股有限责任公司 囊泡
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
GB201505532D0 (en) * 2015-03-31 2015-05-13 Sequessome Technology Holdings Ltd Formulations
ES2895910T3 (es) 2015-06-30 2022-02-23 Sequessome Tech Holdings Limited Composiciones multifásicas
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
CN114507408A (zh) * 2022-03-02 2022-05-17 陕西科技大学 一种低摩擦、模量可调的物理水凝胶及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2067754C (en) 1990-08-24 2002-06-04 Gregor Cevc Preparation for the application of agents in mini-droplets
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
AU4327193A (en) * 1992-07-08 1994-01-31 Dianorm-Gerate G. Maierhofer Liposomes, method of preparing them and their use in the preparation of drugs
DE4447287C1 (de) 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US5902604A (en) * 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
KR20010106462A (ko) * 1998-09-01 2001-11-29 체에베체 그레고르 배리어를 가로지른 대전 침투제의 전기적으로 제어된수송
TR200101790T2 (tr) * 1998-12-23 2001-10-22 Idea Ag. Yayılgan olmayan in vivo topik uygulamalar için geliştirilmiş formül
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
TWI281407B (en) * 2000-09-18 2007-05-21 Vasogen Ireland Ltd Apoptosis-mimicking synthetic entities and use thereof in medical treatment
US20030064948A1 (en) * 2001-02-08 2003-04-03 Alfred Fahr Invasomes for therapy of disorders, their preparation and use
US20040009216A1 (en) * 2002-04-05 2004-01-15 Rodrigueza Wendi V. Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
JP2004131432A (ja) * 2002-10-11 2004-04-30 Kumamoto Technology & Industry Foundation 悪性腫瘍抑制剤
KR20050055723A (ko) * 2002-10-11 2005-06-13 이데아 아게 생체 내, 특히 피부를 통한 비침투성 약물 적용 및 반투성배리어를 통한 향상된 전달을 위한, 적어도 세 가지 양친성성분을 포함하는, 증가된 변형성을 갖는 응집체
US7473432B2 (en) 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
JP2006525368A (ja) * 2003-05-02 2006-11-09 アロネックス，ファーマシューティカルズ，インコーポレーテッド 脂質白金錯体およびその使用方法
EA200600297A1 (ru) * 2003-07-21 2006-08-25 Васоджен Айеленд Лимитед Лечение острого воспалительного состояния
WO2006086992A2 (en) * 2005-02-18 2006-08-24 Liplasome Pharma A/S Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands
ES2599630T3 (es) * 2006-09-28 2017-02-02 Hadasit Medical Research Services & Development Limited Uso de glicerofosfolípidos para lubricación de las articulaciones

Also Published As

Publication number Publication date
PL2437726T3 (pl) 2018-12-31
EP2437726A2 (en) 2012-04-11
CN105434353A (zh) 2016-03-30
CO6480985A2 (es) 2012-07-16
WO2010140061A3 (en) 2011-07-28
CN105434354A (zh) 2016-03-30
DE112010001765T5 (de) 2012-12-27
LT2437726T (lt) 2018-09-10
KR20140021950A (ko) 2014-02-21
GB201122433D0 (en) 2012-02-08
GB2483419B (en) 2015-04-08
WO2010140061A2 (en) 2010-12-09
EA029132B1 (ru) 2018-02-28
AU2010255391A1 (en) 2012-02-02
AU2010255391B2 (en) 2016-06-02
CN105434329A (zh) 2016-03-30
NZ597419A (en) 2014-01-31
AU2010255391C1 (en) 2016-10-27
ES2682075T3 (es) 2018-09-18
BRPI1010861A8 (pt) 2023-01-24
US20160175448A1 (en) 2016-06-23
JP2012528846A (ja) 2012-11-15
US20120220669A1 (en) 2012-08-30
MX349417B (es) 2017-07-28
MY170121A (en) 2019-07-05
DK2437726T3 (en) 2018-08-13
MX2011012754A (es) 2012-07-25
CA2764227C (en) 2016-12-06
SG176297A1 (en) 2012-01-30
CA2764227A1 (en) 2010-12-09
EA201190344A1 (ru) 2012-09-28
IL216737A (en) 2016-09-29
IL216737A0 (en) 2012-02-29
JP2015193629A (ja) 2015-11-05
ZA201200017B (en) 2019-01-30
BRPI1010861A2 (pt) 2018-06-12
CN102639113A (zh) 2012-08-15
GB2483419A (en) 2012-03-07
EP2437726B1 (en) 2018-05-16
PT2437726T (pt) 2018-08-10

Similar Documents

Publication Publication Date Title
CL2011003065A1 (es) Formulacion vesicular que comprende uno o mas fosfolipidos y uno o mas surfactantes no ionicos, libre de cualquier agente farmaceuticamente activo, util para el tratamiento del dolor asociado con osteoartritis.
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
BR112014004460A2 (pt) material polimérico para um recipiente isolado
CR20120345A (es) Derivados de 3-hidroxi-5-arilisotiazol novedosos
CL2012000446A1 (es) Uso de una formulación vesicular tópica que comprende uno o más fosfolípidos y uno o más tensoactivos en una razón molar de 1:1 a 25:1 de fosfolípidos a tensoactivos, para el tratamiento de trastornos dermatosos inflamatorios.
BR112014019262A8 (pt) Composições orais veterinárias parasíticas compreendendo ingredientes ativos de ação sistêmica, métodos e uso das mesmas
CL2012001583A1 (es) Preparación oftálmica que comprende: a) povidona yodada, b) un agente refrescante y c) uno o más entre alcanfor, borneol, lubricante, emoliente, antiinflamatorio esteroidal y antinflamatorio no esteroidal; y su uso para el tratamiento y/o profilaxis de un trastorno ocular o una infección.
CL2015002736A1 (es) Composición farmacéutica de clorhidrato de s-ketamina.
ECSP088239A (es) Composición de liberación de fármaco sostenida
PE20120326A1 (es) Formulaciones farmaceuticas para reducir la proliferacion y viabilidad de los agentes microbianos
ATE534378T1 (de) Titrierung von tapentadol
BR112012020731A2 (pt) pastilhas gelatinosas suaves com nicotina.
CR20110599A (es) Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
CL2010001620A1 (es) Composicion agricola, del cuidado personal, del cuidado de la casa y de revestimiento que comprende silicona y otro componente adicional; emulsion acuosa y no acuosa que comprende la composicion agricola; y metodo para formular dichas composiciones (div. sol. n° 656-207).
AR082155A1 (es) Formulacion antiseptica y desinfectante que tiene contenido de yodo reducido
PE20140255A1 (es) Tableta dispersable en forma oral
BR112017026303A2 (pt) composição de lenço com gel compreendendo fibra de gel superabsorvente
PE20121709A1 (es) Una composicion farmaceutica para tratar cancer que comprende tripsinogeno y/o quimotripsinogeno y un agente activo seleccionado a partir de un compuesto de selenio, un compuesto vainilloide y un agente reductor de glicolisis citoplasmica
CL2011003327A1 (es) Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales.
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CL2015002817A1 (es) Formulación del l-5-metiltetrahidrofolato de calcio amorfo (l-5-mthf-ca).
DOP2016000007A (es) Pirazolpiridinas sustituidas
CL2012000611A1 (es) Compuesto 5-(3,4-dicloro-fenil)-n-(2-hidroxi-ciclohexil)-6-(2,2,2- trifluoro-etoxi)-nicotinamida, util como agente que aumenta el colesterol hdl; proceso de obtencion del compuesto; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la aterosclerosis, dislipidemia, enfermedades cardiovasculares, entre otras.